yi ben zhuan zhu yu yi yao ke ji qian yan yu yan fa dong tai de zhuan ye mei ti yao xue jin zhan

..............page:557

Expert Interpretations of New Polices on Drug Evaluation Reform
Editorial Board of Progress in Pharmaceutical Sciences;

..............page:561-565

Policies, Strategies and Practices of Orphan Drug Development in the United States
DU Tao;GONG Zhaolong;GAO Yi;Humphries Pharmaceutical Consulting;LLC;3D Medicines Inc.;

..............page:566-570

zhong guo yao ke da xue xue bao 2016 nian zheng ding qi shi

..............page:570

Discussion and Thinking on Compulsory Licensing for Drug Patents
ZHANG Qingkui;LI Hongtuan;Department of Retired People;State Intellectual Property Office of the P.R.China;Hebei Institute of Coal Geology;

..............page:571-576

A Probe into the Review Mode of Novelty Presumption and the Principles of the Allocation of Burden of Proof——Analysis of a Hot Issue on the Novelty Judgement of Pharmaceutical and Biotechnology Patents
WEI Cong;The Second Pharmacy and Biotech Appeal Division;The Patent Reexamination Board of the State Intellectual Property Office of the P.R.China;

..............page:577-581

Interpretation and Infringement Judgment of the Closed Patent Claims to Pharmaceutical Compositions——Based on a Case Judged by the Supreme People’s Court
YIN Xin;The Patent Reexamination Board of the State Intellectual Property Office of the P.R.China;

..............page:582-587

zhong guo yao xue nian jian 2014 juan zheng ding qi shi

..............page:587

Effect of the Features of Drug-Administrated Objects on the Patent Claims of Medical Use Inventions——Taking a Patent Dispute Case between Bristol-Myers Squibb Company and Chia Tai Tianqing Pharmaceutical Co., Ltd. for Example
WANG Dong;The First Pharmacy and Biotech Appeal Division;The Patent Reexamination Board of the State Intellectual Property Office of the P.R.China;

..............page:588-591

Advances in Researches on Pathogenesis and Treatment of Sleep Disorders in Patients with Parkinson’s Disease
HAN Rui;CHEN Rong;Department of Pharmacy;the First People’s Hospital of Changzhou;

..............page:592-597

yao xue jin zhan za zhi 2015 nian zheng ding qi shi

..............page:597

Advances on Anticancer Antibiotic Geldanamycin Derivative 17AAG
YI Fengyan;ZHOU Changlin;GU Juefen;School of Life Science and Technology;China Pharmaceutical University;Nantong QZU Bioscience & Biotechnology Co.Ltd;

..............page:598-602

Report on Therapeutic Monoclonal Antibody——Painful Efforts Translate into Fruitful Gains(Ⅱ)
SUN Jian;Institute of Qilu Securities;

..............page:603-607

Blue Book on the Development of China’s Medical and Pharmaceutical Market in 2015——Part of Terminal Market in Public Hospitals(Ⅲ)
MENET;

..............page:608-622

World Preview 2015,Outlook to 2020(Ⅰ)
Evaluate Pharma;

..............page:623-628

Notable Deals in the Pharmaceutical Industry in Q2 2015
Thomson Reuters;

..............page:629-633

Palbociclib—a New Drug Approved for Advanced Breast Cancer
LIU Shu;XU Jun;CUI Yi;SU Yangyang;Pharmacodia Co.;Ltd;

..............page:634-640